Alyssum Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
626 Massachusetts Ave Fl 2, Cambridge, M...Website
www.alyssumtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Alyssum Therapeutics
Alyssum Therapeutics is focused on pioneering B cell immunotherapy to regulate the B cell immune response for treating complex diseases. Their lead candidate, AT1965, is currently in Phase 1 clinical trials for advanced solid malignancies, showing promise in regressing hard-to-treat tumors. The company aims to transform patient lives by modulating B cells, which play a crucial role in the immune response against various conditions, including cancer and autoimmune diseases. Their innovative approach seeks to enhance survival outcomes in patients with solid tumors through comprehensive immune activation.Explore more
Popular SearchesAlyssum Therapeutics IncSIC Code 28,283NAICS Code 32,325Show more
Alyssum Therapeutics Org Chart
AB
Lead, Clinical Operations
TA
Chief Development Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alyssum Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alyssum Therapeutics launches new products
Alyssum Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Alyssum Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Alyssum Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Alyssum Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Alyssum Therapeutics
Check out if Alyssum Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Alyssum Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Alyssum Therapeutics
Compare insights from companies similar to Alyssum Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alyssum Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alyssum Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alyssum Therapeutics.
Alyssum Therapeutics financials insights
Gather financial insights about Alyssum Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$26.5M
Alyssum Therapeutics Tech Stack
A closer look at the technologies used by Alyssum Therapeutics
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alyssum Therapeutics
Sign Up For FreeTo access detailed company insights
Alyssum Therapeutics is focused on pioneering B cell immunotherapy to regulate the B cell immune response for treating complex diseases. Their lead candidate, AT1965, is currently in Phase 1 clinical trials for advanced solid malignancies, showing promise in regressing hard-to-treat tumors. The company aims to transform patient lives by modulating... Read More
